Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Operating Leases: 2019-2020

Historic Operating Leases for Larimar Therapeutics (LRMR) over the last 2 years, with Sep 2020 value amounting to $6.1 million.

  • Larimar Therapeutics' Operating Leases fell 5.60% to $6.1 million in Q3 2020 from the same period last year, while for Sep 2020 it was $6.1 million, marking a year-over-year decrease of 5.60%. This contributed to the annual value of $6.5 million for FY2019, which is N/A change from last year.
  • Larimar Therapeutics' Operating Leases amounted to $6.1 million in Q3 2020, which was down 2.07% from $6.3 million recorded in Q2 2020.
  • Over the past 5 years, Larimar Therapeutics' Operating Leases peaked at $6.5 million during Q3 2019, and registered a low of $567,000 during Q1 2019.
  • Over the past 2 years, Larimar Therapeutics' median Operating Leases value was $6.3 million (recorded in 2020), while the average stood at $5.5 million.
  • The largest annual percentage gain for Larimar Therapeutics' Operating Leases in the last 5 years was 1,019.22% (2020), contrasted with its biggest fall of 5.60% (2020).
  • Larimar Therapeutics' Operating Leases (Quarterly) stood at $6.5 million in 2019, then dropped by 5.60% to $6.1 million in 2020.
  • Its Operating Leases was $6.1 million in Q3 2020, compared to $6.3 million in Q2 2020 and $6.3 million in Q1 2020.